P
roteins, rather than genes, can be directly and readily introduced into cells when fused with the protein transduction domain (PTD) of HIV͞Tat protein (1) . In fact, PTD-fused proteins can be successfully delivered to several tissues, including the brain when injected into mice systemically (2) . Although this technology was originally described in 1994 (3) and many proteins fused with the PTD have been introduced into cells in vitro and in vivo (2, 4) , few animal models of disease or injury have successfully precluded necrosis as well as apoptosis, by treating with transducing full-length therapeutic proteins. Demonstrating the in vivo efficacy of proteins with strong therapeutic activity would be important for practical applications.
Because antiapoptotic factors prevent presumed necrosis as well as apoptosis (5) , preventing massive cell death by antiapoptotic factors could be an efficacious strategy for the treatment of various disorders and injuries. Antiapoptotic members of the Bcl-2 family, Bcl-2 and Bcl-x L , are good candidates for protein therapeutics. They interact with the proapoptotic Bcl-2 family members to neutralize apoptotic activity and are localized mainly in mitochondria to regulate the release of cytochrome c (6, 7) . Virus-mediated transfer of the bcl-2 gene into the brain has been shown to inhibit neuronal cell death induced by stroke, ischemia, and 6-hydroxydopamine (8) (9) (10) (11) (12) . Delivery of the bcl-2 and bcl-x genes by particle gun also prolonged neuronal survival (13) . However, these applications have difficulties expressing sufficient amounts of the active proteins in a short time to prevent cell death in acute cases. In addition, gene therapy approaches cannot exclude the possibility of hazardous insertions of transgenes.
Because antiapoptotic activity of Bcl-2 and Bcl-x L is suppressed by phosphorylation, mutants of Bcl-2 and Bcl-x L that lack their phosphorylation sites have been generated to prevent a loss of function (14, 15) . We have constructed a powerful artificial cytoprotective protein, FNK (originally designated Bcl-xFNK in ref. 16 ) from Bcl-x L (17) by site-directed mutagenesis, based on the high-resolution crystal structure of the rat Bcl-x L (18) . FNK has three amino acid substitutions, Tyr-22 to Phe (F), Gln-26 to Asn (N), and Arg-165 to Lys (K), in which three hydrogen bonds stabilizing the central ␣5-␣6 helices (the putative pore-forming domain) are abolished. Compared with Bcl-x L , FNK protects cultured cells more potently from cell death induced by oxidative stress (hydrogen peroxide and paraquat), a calcium ionophore (A23187), growth factor withdraw (serum and IL-3), anti-Fas, cell cycle inhibitors (TN-16, camptothecin, hydroxyurea, and trichostatin A), a protein kinase inhibitor (staurosporine, STS), and heat treatment (16) . FNK is the first and sole mutant with a gain-of-function phenotype among the mammalian antiapoptotic factors. To test the efficacy of FNK in preventing neuronal cell death induced by injuries in vivo, we generated PTD-FNK fusion protein by fusing FNK with the PTD of HIV͞Tat. Here, we show that PTD-FNK protects cultured neuronal cells against neuroexcitoxicity as well as apoptosis and that treatment of gerbils with PTD-FNK successfully reduces ischemic injury of hippocampal CA1 neurons.
Materials and Methods

Construction and Preparation of PTD-FNK, PTD-Bcl-xL, and PTD-myc-
FNK. An oligonucleotide encoding MGYGRKKRRQRRRG (the TAT protein transduction domain of 11 aa is underlined) (1) was ligated to the 5Ј end of FNK or Bcl-x L coding sequence by PCR to construct PTD-FNK or PTD-Bcl-x L, respectively. An oligonucleotide encoding GEQKLISEEDLG (myc TAG sequence is underlined) was inserted between the PTD and FNK sequences of PTD-FNK by PCR to obtain PTD-myc-FNK. The ligated DNA fragment was inserted between the NcoI and HindIII sites of the pPROEX1 expression vector (Invitrogen). The coding region of FNK was also cloned into the vector. The integrity of the constructs was confirmed by DNA sequencing. The resultant plasmids were introduced into Escherichia coli DH5␣MCR (Invitrogen), followed by induction of expression with isopropyl 1-thio-␤-D-galactoside. The induced proteins were recovered as inclusion bodies. To prepare PTD-FNK, PTD-Bcl-x L , and FNK for in vitro experiments, the inclusion bodies were solubilized with 7 M urea, 1 mM DTT, 50 mM Tris⅐HCl (pH 8.0), and 150 mM NaCl, and finally dialyzed against saline containing 33% PBS. After a brief centrifugation, the soluble fraction was added into the media for neuroblasto-mas or primary neocortical neurons. Protein purity and concentration were confirmed by SDS͞PAGE. To prepare PTD-FNK and PTD-myc-FNK for in vivo injections, the inclusion bodies were solubilized in a buffer containing 7 M urea, 2% SDS, 1 mM DTT, 62.5 mM Tris⅐HCl (pH 6.8), and 150 mM NaCl. The PTD-FNK extracted was then subjected to SDS͞PAGE to remove endotoxin and contaminated proteins. The gel was briefly immersed in 1 M KCl, which makes an insoluble complex with free SDS, and a band corresponding to PTD-FNK (transparent because of reduced free SDS) was cut out. PTD-FNK was electrophoretically extracted from the gel slice in extraction buffer (25 mM Tris͞0.2 M glycine͞0.1% SDS) and was injected into animals. The extraction buffer was used as a control (vehicle). The concentration of extracted PTD-FNK ranged from 1 to 2 mg͞ml. Protein concentration was determined by Coomassie brilliant blue staining after SDS͞PAGE, followed by comparison with BSA standard.
Cell Culture. Neuroblastoma SH-SY5Y cells were cultured in DMEM (Invitrogen) with 15% FBS and 20 units͞ml penicillin-20 g͞ml streptomycin. Primary cultures of neocortical neurons were prepared from 18-day rat embryos as described (19, 20) with slight modifications. In brief, neocortical tissues were cleaned of meninges, minced, and treated with 0.25% trypsin and 0.01% DNase I. After mechanical dissociation by pipetting, cells were resuspended in MEM (Invitrogen) supplemented with 25 mM Hepes buffer, 10 g͞ml insulin, 5.5 g͞ml transferrin, 100 M putrescine, 6.7 ng͞ml sodium selenite, and 50 units͞ml penicillin-100 g͞ml streptomycin, and then plated onto poly-L-lysine-coated plates at a density of 1 ϫ 10
Neurons were used at days 6-8. Neuronal identity was confirmed by immunostaining with anti-MAP2 (a marker of neurons; Sigma), anti-glial fibrillary acidic protein (a marker of astrocyte; Immunon, Pittsburgh), and anti-Nestin (a marker of neural stem cells; PharMingen). Preparations containing Ͼ95% neurons were used for experiments.
Immunostaining. Cell cultures were prepared on 4-well plastic dishes (SonicSeal Slide, Nalge Nunc). The cells were rinsed with PBS and fixed in 4% paraformaldehyde in PBS for 30 min. After washing with PBS, the cells were incubated for 30 min in 0.2% Triton X-100, 30 min in a blocking buffer (3% BSA and 3% goat serum in PBS), and overnight at 4°C in a blocking buffer containing primary antibody. After another wash with PBS, cells were incubated in a blocking buffer containing BODIPY FL goat anti-mouse IgG (1:500, Molecular Probes) for 1 h and imaged with a confocal scanning microscope Fluoroview FV͞300 (Olympus, Tokyo) using excitation and emission filters of 488 and 510 nm, respectively. Monoclonal anti-Bcl-x (no. 35-32) antibody was prepared as described (21) . Because this antibody recognizes its N-terminal region, the amino acid alterations in FNK would not affect the affinity to the antibody. When cells were prestained with 100 nM MitoTracker red, its fluorescence was imaged with excitation and emission filters of 543 and 565 nm, respectively.
STS-Inducing Apoptosis of SH-SY5Y.
After incubation with 800 nM STS for 1 day, 5 M propidium iodide (PI, for detecting dead nuclei) and 5 M Hoechst 33342 (for detecting living nuclei) were added to each well containing SH-SY5Y that had been pretreated with a given concentration of PTD-FNK or vehicle. Cells stained with either dye were counted per well. Viability was calculated as follows: 100 ϫ (1 Ϫ PI-stained cells͞total cells).
Exposure of Neurons to Glutamate. Cells were preincubated with PTD-FNK at a given concentration or vehicle for 2 h. For the determination of cell survival, neurons were washed once with Hanks' balanced salt solution (HBSS) with 2 mM CaCl 2 and exposed to 1 mM L-glutamate in HBSS containing 2 mM CaCl 2 at 37°C for 1 h. Then, HBSS was replaced with the medium and incubated for 1 day. Viable neurons with a triangular soma and neurites were enumerated under a phase-contrast microscope (ϫ200) in five fields per well for four independent wells.
For the determination of a transient elevation in intracellular free Ca 2ϩ ([Ca 2ϩ ] i ) the fluorescence Ca 2ϩ indicator Fluo-3 AM (Molecular Probes) was added to the medium at a final concentration of 5 M and incubated for 30 min. Then, neurons were washed once with HBSS containing 2 mM CaCl 2 and exposed to 1 mM L-glutamate for a period. Fluorescence was imaged by confocal scanning microscopy using excitation and emission filters of 488 and 510 nm, respectively. Images obtained every 5 s were analyzed by using the NIH IMAGE program. Analysis of data were performed as described (22, 23) .
Immunohistochemical Staining of Brain Sections. Male C57BL͞6N mice (4 weeks old; Seac Yoshitomi, Fukuoka, Japan) were used. To examine the distribution of PTD-myc-FNK (50 mg͞kg) delivered the brain at 10 h after its i.p. injection, mice were killed with an overdose of pentobarbital and perfused transcardially with cold heparinized physiological saline followed by 4% paraformaldehyde in PBS. Brains were removed, fixed by immersion into 4% paraformaldehyde in PBS overnight at 4°C, dehydrated, and embedded in paraffin. Paraffin sections (4 m) were prepared for immunohistochemical staining. To detect PTD-myc-FNK in situ, rabbit anti-Myc Tag polyclonal antibody (1:50, 4°C overnight, Upstate Biotechnology, Lake Placid, NY) was used coupled with a DAKO Envision ϩ system. Cerebral Ischemia. Male Mongolian gerbils (Hoshino Laboratory Animals, Saitama, Japan), weighing 60-80 g, were injected i.p. with vehicle or PTD-FNK (5 mg͞kg) 3 h before ischemic insults. Ischemia was induced for 5 min by occluding the common carotid arteries bilaterally with aneurysm clips under halothane anesthesia (1.5%) in N 2 O͞O 2 (70:30) (24, 25) . Rectal and temporal muscle temperatures were maintained close to 37°C during ischemia and the first 6 h of reperfusion. Seven days later, the brains were transcardially perfused with 4% formaldehyde in 0.1 M phosphate buffer (pH 7.4). Then, 5-m-thick paraffin cross sections containing hippocampal tissue were stained with hematoxylin-eosin. Intact neurons with distinct nuclei were counted per 1-mm CA1 length on each side, and the average was expressed as neuronal cell density (cells per mm).
Animal protocols were approved by the Animal Care and Use Committee of Nippon Medical School.
Results and Discussion
Transduction of PTD-FNK into Neuroblastoma Cells and Primary Cultured Neocortical Neurons. To examine the ability and time course of the PTD-FNK protein to transfer into cells, 30 nM PTD-FNK was added to culture medium of the neuroblastoma cell line, SH-SY5Y, and incubated for the indicated periods ( Fig. 1 A and  C) . The cells were cotreated with 100 nM MitoTracker red, a fluorescent indicator of mitochondria, for 10 min just before stopping the incubation with PTD-FNK and fixed with paraformaldehyde. The cells were stained with anti-Bcl-x mAb and the fluorescence was detected by confocal scanning fluorescent microscopy. Green fluorescence indicating Bcl-x derivatives was faint at time 0, but increased over time, achieving a steady-state level in Ϸ1 h. The PTD-FNK protein was observed to transduce into virtually all of the cells. In addition, the majority of green fluorescence colocalized with the red fluorescence of MitoTracker red as revealed by the merged images. The decay of the PTD-FNK protein was examined, revealing that the half-span of the incorporated protein is Ϸ2 h (Fig. 1D) .
To study the concentration of intracellular protein delivery, neocortical neurons were prepared from rat embryos and treated with 30 or 300 nM PTD-FNK for 30 min. Endogenous Bcl-x L protein gave punctate fluorescent signal and appeared to colocalize with mitochondria. In neurons incubated with PTD-FNK, the intense green fluorescent signals increased depending on PTD-FNK concentration and colocalized with the red fluorescence from MitoTracker red ( Fig. 1 B and C Right) . Taken The mean of three to four independent experiments is presented with SD (vertical bars). * , P Ͻ 0.01; ** , P Ͻ 0.001, compared with no PTD-FNK by one-way ANOVA. together, these observations indicate that PTD-FNK is rapidly transduced into neuroblastomas or primary cultured neurons and localizes to mitochondria.
Protection of Neuronal Cell Death by PTD-FNK Transduction in Vitro.
To examine the cytoprotective activity of PTD-FNK after transduction into cells, we performed two in vitro cell-death protection experiments on (i) STS-induced apoptosis of SH-SY5Y cells (26) and (ii) glutamate excitotoxicity of primary neocortical neurons (27) .
As expected, STS induced apoptosis in SH-SY5Y cells as judged by nuclear fragmentation (Fig. 2 C-E) . The PTD-FNK protein markedly inhibited cell death in a PTD-FNK concentration-manner (Fig. 2 A) . More importantly, PTD-FNK was more potent in inhibiting cell death compared with its WT version PTD-Bcl-x L and FNK itself (Fig. 2B) .
To induce excitotoxicity, neocortical neurons that had been pretreated with 30 nM PTD-FNK for 2 h were incubated with HBSS containing 2 mM CaCl 2 and 1 mM glutamate for 1 h. Neurons were washed with HBSS in the absence of Ca 2ϩ and glutamate and placed in complete medium for 24 h, and then viable cells were counted under a microscope. PTD-FNK markedly reduced glutamate-induced toxicity (Fig. 3 A and C) . The cytoprotective effect of PTD-FNK was maximum at 3 pM to 3 nM. Interestingly, PTD-FNK significantly protected neurons from glutamate excitotoxicity at concentrations as low as 0.3 pM. Next, we compared the cytoprotective effect of PTD-FNK with that of PTD-Bcl-x L or the FNK protein without PTD at 30 pM (Fig. 3B) . PTD-FNK was twice as effective as PTD-Bcl-x L in protecting neurons. Glutamate excitotoxicity is widely considered to induce necrotic cell death (28) . Thus, PTD-FNK appeared to inhibit necrosis in addition to apoptosis. The latter observation is not surprising because FNK gene expression prevents against cell death induced by a calcium ionophore (16) .
We also examined how PTD-FNK protects neurons against the excitotoxicity. Cultured neocortical neurons treated with or without PTD-FNK were placed in HBSS containing 2 mM CaCl 2 and Fluo-3 AM to measure [Ca 2ϩ ] i . Fluorescence signal intensity was monitored from 20 neurons for 2 h by confocal scanning fluorescent microscopy. [Ca 2ϩ ] i increased rapidly after the addition of glutamate and gradually to reach a plateau. The second increase of [Ca 2ϩ ] i clearly occurred Ϸ50 min later in 55-60% (11-12͞20) of the neurons monitored (Fig. 3D Left) . This finding agrees with previous reports (22) and the second increase could be responsible for neuronal cell death (23) . In contrast, the second increase in [Ca 2ϩ ] i was observed significantly in only 20% (4͞20) of the neurons that had been pretreated with 3 nM PTD-FNK during the measurement time (P ϭ 0.02 by the Mann-Whitney U test). Thus, these experiments suggest that PTD-FNK affects the movement of calcium ions, leading to the protection against excitotoxicity, directly or indirectly. 
Cerebral Ischemic Damage Reduced by PTD-FNK Transduction in Vivo.
To test whether PTD-FNK can be delivered into neurons in the brain, myc-tagged PTD-FNK (PTD-myc-FNK) was first injected i.p. into a mouse. Immunohistochemical staining using anti-myctag antibody revealed strong immunoreactivity in the microvessels as well as the cytoplasm of cortical neurons, compared with those of a control mouse injected with vehicle ( Fig. 4 A and B) , indicating that PTD-FNK can indeed cross the blood-brain barrier and get into the neuronal cells. Transient global ischemia causes the slow progressive degeneration of hippocampal CA1 neurons in gerbils. Glutamate release and apoptotic regulation have been shown to contribute to delayed-neuronal cell death (29) (30) (31) (32) (33) (34) . We chose ischemic brain injury as a model system to test the cytoprotective effect of PTD-FNK in vivo.
We asked whether in vivo injection of PTD-FNK could protect CA1 neurons against ischemic damage. In control gerbils injected with vehicle, fewer than 1% of CA1 neurons survived the ischemic insult (Fig. 4 C-E) . In contrast, injection of PTD-FNK apparently inhibited the delayed neuronal cell death (Fig. 4 C  and F-I) . The magnitude of the protective effect of PTD-FNK ranged from 16% to 89% survival of CA1 neurons (Fig. 4C) , which is statistically significant. A neuronal survival of 89% in ischemic insult suggests that PTD-FNK is as effective as ischemic preconditioning of 2 min (24) and mild hypothermia (35) and much more effective than virus-mediated introduction of the bcl-2 gene (12). As shown in this study, the neuroblastomas and primary neurons transduced with a low amount of PTD-FNK (pM order) exhibited resistance to STS-inducing apoptosis and glutamate excitotoxicity in vitro, respectively. Thus, it is a plausible explanation that PTD-FNK delivered to CA1 neurons protects cells from death caused by the collapse of Ca 2ϩ homeostasis and͞or oxidative stress caused by ischemic insult as suggested by our in vitro experiments (16) . Additionally, cells of the other types, such as endothelial and glial cells, transduced with PTD-FNK may also contribute to the amelioration of the ischemic brain injury.
The induction of hypothermia is known to inhibit neuronal death after ischemia (35) . Because the gerbils were kept at 37°C for 6 h after the ischemic episode, it is unlikely that the anti-ischemic efficacy of PTD-FNK is mediated through its hypothermic properties. Thus, a greater synergistic effect may be expected on combining PTD-FNK injection with hypothermic treatment.
In conclusion, PTD-FNK injected into rodents can be successfully delivered to the brain and prevents the slow progressive death of neurons. Proteins delivered into cells by this strategy would remain in cells only transiently. In addition, transgenic mice expressing FNK have shown no particular phenotype, indicating lack of gross adverse effects (unpublished work). Thus, the toxicity of PTD-FNK would not be critical. PTD-FNK was delivered in a neuroprotective paradigm before the brain insult in this study. Because neurons die in a week after the ischemic insult, this strategy may be useful as the neurorestorative treatment. The therapeutic time frame and effective administration protocols remain to be determined. Thus, time course and dose effects need to be investigated in the near future for details. In addition, the careful comparison of PTD-FNK with PTD-Bcl-x L or FNK itself may be required.
Cao et al. (36) have recently reported that PTD-Bcl-x L inhibited STS-induced apoptosis in primary cultured neocortical neurons and that PTD-Bcl-x L delivered to the brain when i.p. injected and inhibited neuronal cell death induced by transient focal ischemia. Because pancreatic islets transduced with PTDBcl-x L fusion protein in vitro were more resistant to apoptosis and were transplanted without functional failure (37) , PTD-FNK is also expected to be more useful for the transplantation of organs or tissues. Our results strongly suggest that PTD-FNK is a potent protein with various therapeutic applications.
